Trial Profile
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Avapritinib (Primary)
- Indications Mast Cell Leukemia; Systemic mastocytosis
- Focus Registrational; Therapeutic Use
- Acronyms PATHFINDER
- Sponsors Blueprint Medicines
- 01 Aug 2023 Planned End Date changed from 1 Jan 2026 to 31 Jan 2026.
- 01 Aug 2023 Planned primary completion date changed from 1 Jan 2026 to 31 Jan 2026.
- 15 Jun 2023 Results assessing efficacy and safety Avapritinib in patients with advanced systemic mastocytosis with a 2-year follow-up presented at the 28th Congress of the European Haematology Association